Sleep Management with Melatonin and Psychotropic Medications

Introduction to Melatonin Safety

Melatonin is a safer option for sleep management compared to benzodiazepines, with no risks of cognitive impairment, dependence, or significant morning sedation 1

The American Academy of Sleep Medicine recommends prioritizing non-pharmacological approaches, such as maintaining consistent sleep-wake schedules, creating a dark, quiet, and cool bedroom environment, reducing evening exposure to blue light from electronic devices, and considering cognitive behavioral therapy for insomnia (CBT-I) 2
If pharmacological intervention is necessary, the American Academy of Sleep Medicine suggests a sequence for insomnia treatment, including short-intermediate acting benzodiazepine receptor agonists or ramelteon, sedating antidepressants, and combined approaches 2

Caution should be exercised when combining multiple serotonergic agents, as there is a minimal risk of serotonin syndrome with melatonin compared to other sleep medications 3

Starting with a low dose of melatonin (1-2 mg) and monitoring for excessive sedation or changes in mood, especially during the first few days of combined use, is recommended 1
The American Academy of Sleep Medicine clinical practice guidelines do not strongly recommend melatonin for treating either sleep onset or sleep maintenance insomnia, with melatonin (2 mg) showing only modest benefits, including a mean reduction in sleep latency of 9 minutes compared to placebo, and small improvement in quality of sleep, with limited adverse effects 4
Melatonin should be administered on an empty stomach to maximize effectiveness, and 1-2 hours before bedtime, with a typical target bedtime of 10 pm to midnight 4, 2

The following table summarizes the recommended dosages for different populations:

Population	Recommended Dosage
Children with DSWPD and no comorbidities	0.15 mg/kg taken 1.5-2 hours before habitual bedtime
Children with DSWPD and psychiatric comorbidities	3-5 mg (weight-based) taken at 18:00 or 19:00
Adults	1-5 mg approximately 1-2 hours before bedtime for optimal effectiveness
Adults with DSWPD	5 mg taken between 7:00-9:00 PM
Patients with REM Sleep Behavior Disorder	starting with 3 mg at bedtime, which may be titrated up to 15 mg if needed
Elderly patients	starting with lower doses (1-2 mg) and titrating as needed

5, 6, 7

Melatonin efficacy and safety concerns for different populations are as follows:

Population	Efficacy	Safety Concerns
General adults	Modest effect on sleep onset	Few mild-moderate adverse events
Children with neurodevelopmental disorders	Effective for sleep onset	Potential hormonal effects with long-term use
Elderly	May be beneficial at lower doses	Start with lower doses (1-2 mg)

The American Academy of Sleep Medicine recommends that melatonin should be part of a broader approach to improving sleep in the hospital setting, including non-pharmacological interventions such as reducing noise and light exposure, maintaining consistent sleep-wake schedules when possible, and creating a comfortable sleep environment 9
Reduce evening exposure to blue light from electronic devices, use blue-light blocking glasses in the evening, set devices to night shift mode and lower brightness, and use low correlated color temperature (CCT) lighting (2000K) in bedrooms to improve sleep quality 10
Remove electronic devices from the bedroom to minimize sleep disturbances 10
Maintain consistent sleep-wake schedules, even on weekends, to regulate the body's internal clock 11
Create a dark, quiet, and cool bedroom environment to promote better sleep 11

Patients with epilepsy, hepatic impairment, or those taking warfarin require special caution due to potential interactions, and patients on multiple medications should consider potential drug interactions with melatonin, as advised by the American Academy of Sleep Medicine 5, 4, 8
Key concerns with melatonin use in children include potential effects on growth hormone regulation and possible impacts on reproductive function/development, and monitoring for adverse effects including daytime drowsiness, headache, dizziness, changes in mood, and potential hormonal effects with long-term use is necessary, as recommended by the American Academy of Sleep Medicine 5, 4, 8
Regular monitoring for efficacy and side effects, as well as periodic attempts to discontinue melatonin treatment to assess continued need, are essential, according to the American Academy of Sleep Medicine, with a strength of evidence supporting this recommendation 5, 8

For Delayed Sleep-Wake Phase Disorder (DSWPD), morning bright light therapy, consistent sleep-wake scheduling, and a combination of light therapy and behavioral interventions are recommended (WEAK FOR recommendation) 5
For Insomnia, cognitive-behavioral therapy for insomnia (CBT-I) is recommended 8
For Insomnia, consider trazodone as a second-choice pharmacological treatment (based on pediatric psychiatrist prescribing patterns) 12
For Restless Sleep/Periodic Limb Movements, check serum ferritin levels and consider iron supplementation even if blood levels are not low 12
Avoid benzodiazepines due to risk of respiratory depression, ataxia, excessive sedation, and memory impairment 12
Avoid second-generation antipsychotics like quetiapine for sleep disturbances alone due to significant side effects including metabolic syndrome 12
Consider extended-release melatonin formulations for adolescents with neurodevelopmental disorders 12